Genovis’ Board of Directors Has Decided Upon A Private Placement

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Following authorization by the Extraordinary General Meeting of November 19, 2013, Genovis’ Board of Directors has decided upon a private placement of a maximum of 804,643 shares in the company. The subscription period runs until January 20 and the subscription price is SEK 4.50, which is the same as in the rights issue with the subscription period December 2 to 16, 2013.The issue will raise a maximum of SEK 3.6 million for the company and share capital could increase by a maximum of SEK 321,857.20. Following the completed private placement, share capital will amount to a maximum of SEK 8,738,260.80 and the number of shares will be a maximum of 21,845,652. The reason for deviation from shareholders’ preferential rights is to be able to take advantage of interest from underwriters within the framework of issued underwriting guarantees in the rights issue with the subscription period December 2-16, 2013.

Help employers find you! Check out all the jobs and post your resume.

Back to news